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1. Introduction 
Erectile dysfunction (ED) is defined as the persistent inability to maintain or achieve a penile 
erection sufficient for satisfactory sexual performance (1-2). ED is a very common condition 
in middle-aged men (3). According to the National Institute of Health (NIH) this 
physiological disorder affects 30 million men in the United States (US) (2). The outlook for 
2025 is scary because this number is  expected to grow to approximately 322 million (4). 
Although ED is directly associated with aging (5), its etiology is considered multifactorial. 
Both conditions, ED and aging, share a variety of risk factors such as atherosclerosis, 
sedentary lifestyle, abnormal lipids, diabetes, smoking, metabolic syndrome and 
hypertension (2, 6-7). In addition, ED is considered an important marker of cardiovascular 
disease (CVD) (8). Studies over the last decade suggest vascular changes as a common factor 
between ED and CVD (1, 7, 9). Also, the most important vascular alteration mentioned in 
these pathologies cited above is endothelial dysfunction. According to several authors, 
endothelial and smooth muscle dysfunction are crucial factors involved in systemic and 
peripheral vascular diseases, especially ED (10). In this chapter we will discuss the 
association between the main CVD and ED. 
2. ED and atherosclerosis 
Atherosclerosis begins with oxidation of Low Density Lipoproteins (LDL) particles in the 
arterial wall (11). Oxidatively modified LDL (oxLDL) damages the endothelial layer in the 
artery (8, 11), and then the elasticity of the arteries deteriorates. Impaired arterial elasticity 
and increased levels of circulating oxLDL, as well as elevated fibrinogen and resting heart 
rate associated with subclinical atherosclerosis have increased CVD risk (12-17).  
The decrease and/or loss of elasticity impair the blood flow because the cholesterol  
builds up in the blood vessel walls and forms plaque. When plaque becomes very advanced, 
it can completely stop blood from passing through the wall, characterizing a heart  
attack (18). 
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Diseases due to atherosclerosis are common and are becoming a growing health problem in 
industrialized and developing countries, evoking a huge impact on quality of life and life 
expectancy (2, 19). Atherosclerosis affects not only the blood vessels supplying the heart 
(coronary arteries), but also blood vessels throughout the entire body. In addition, various 
alterations disturbing normal body function can occur when atherosclerosis develops 
leading to more complex pathologies such as angina, heart attacks, strokes,  and ED (18). 
The artery size hypothesis is a pathophysiologic mechanism proposed in recent years to 
explain the relationship between ED and coronary artery diseases (CAD) (20). It is based on 
the fact that atherosclerosis, a systemic disorder, should theoretically affect all major 
vascular beds at the same time and extent. However, symptoms at different points in the 
system rarely become evident at the same time. This is probably the result of larger vessels 
being able to better tolerate equivalent amount of plaque compared with smaller ones. The 
diameter of these vessels confirms this idea: penile artery has an arterial diameter of 1-2 
millimeters (mm), coronary artery is 3-4 mm, internal carotid artery is 5-7 mm and femoral 
artery is 6-8 mm. Results from patients with 50% obstruction in the penile artery with no 
coronary circulation critically affected could be explained because larger systemic arteries 
would be impacted later than the smaller penile artery. Thus, it suggests a mechanism for 
the absence of concomitant CAD in early stage ED (20-21).  
 The initial step in the development of atherosclerosis is endothelial dysfunction. Since the 
normal penile erection requires an intact endothelium, it has been proposed that patients 
with ED show a higher probability of developing atherosclerosis (2, 19). Regarding penile 
erection, nitric oxide (NO) plays an important role in physiological conditions. The sexual 
stimulus makes the parasympathetic nerves in the penis produce NO, triggering a cascade 
of events that culminate with increased dilatation of the corpora cavernosum sinusoids to 
induce penile erection. Many other agents are involved in this process that requires a perfect 
balance between vasodilators and vasoconstrictors. Thus, the physiological complexity 
makes it difficult to identify the etiology of ED. As a result, this condition is considered 
multifactorial and includes arterial, neurogenic, hormonal, cavernosal, iatrogenic, and 
psychogenic causes. However, it is now accepted that organic ED, in a substantial majority 
of men, is due to underlying vascular causes (22-23). Endothelial dysfunction is thought to 
be the main etiologic factor in systemic and peripheral vascular diseases, including ED (24). 
It has been associated with impaired vasodilatation, preceding the development of 
atherosclerotic lesions through the impaired release of NO, which is modulated by 
parasympathetic nonadrenergic, noncholinergic nerves (NANC) and by vascular 
endothelial cells (7). Moreover NO production is also influenced by oxidative stress, which 
is deleterious to the endothelium.  
Reactive oxygen species (ROS) are very important in the pathophysiology of vascular 
disease, especially atherosclerosis. Under normal physiological conditions, ROS destruction 
by antioxidant enzymes is sufficient to maintain a controlled activation of signaling 
cascades. In contrast, in vascular diseases, the production of ROS in excess of endogenous 
antioxidant capacity leads to oxidative stress, which in turn results in abnormal 
physiological responses. Interaction between ROS and NO is implicated in many vascular 
diseases such as atherogenesis and play an important role in ED (25). One of the most 
detrimental ROS is superoxide (O2-.), which interacts with NO decreasing NO bioavailability 
and resulting in formation of peroxynitrite (ONOO-). All types of vascular cells produce O2- 
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and H2O2, two of the most significant ROS in the vessel wall. H2O2 can also be metabolized by 
myeloperoxidase, a heme enzyme produced by macrophages that converts H2O2 into reactive 
nitrogen and reactive chlorine. These reactive species can attack both LDL and HDL, 
enhancing cholesterol intake, reducing cholesterol efflux and contributing to plaque formation 
(26). In pathological situations homeostasis disruption by oxidative stress contributes to 
activation of proinflamatory, profibrotic and mitogenic signaling pathways leading to 
oxidative damage in the vasculature which in turn results in increased vasoreactivity, 
endothelial dysfunction, vascular remodeling, reduced vascular compliance and elevated 
blood pressure (BP)(26-28). All these factors also contribute to an increased adhesion and 
aggregation of platelets and neutrophils, and release of vasoconstrictor substances (29-30). 
3. Stroke and ED 
Stroke is a neuroendovascular event resulting in death of brain cells due to an ischemic 
lesion. According to the World Health Organization (WHO), stroke can be classified based 
on the size and site of lesion and its clinical consequences. Most cases of subarachnoid 
hemorrhage, intracranial hemorrhage and cerebral infarction are examples of stroke (31-33). 
Cerebrovascular diseases are the third leading cause of death in the United States, affecting 
5.5 million people a year. When  analyzing diseases that cause long-term  consequences , the 
frequency of stroke is  largest compared with others  (34). Stroke has been responsible for 50 
million deaths worldwide. In adults, cerebrovascular disease is the most frequent pathology 
that induces  severe damage  (35). It is predicted that over the next 20 years, stroke will rise 
from 7th in the DALY league table to 4th, principally influenced by the aging of populations 
especially in less economically developed countries (31, 36).  
It has been hypothesized that ED represents “the tip of the iceberg” of a systemic vascular 
disorder. Thus, ED would potentially precede  larger damage in the body, working as a 
sentinel event  (5). Additionally, ED could be an indicator of potentially life-threatening 
coronary heart disease (CHD), hypertension, hyperlipidemia and stroke (37-42), which are 
diseases that have been the cause  of morbidity and mortality among adults in industrialized 
societies (43). 
In most studies about stroke, only the cognitive and emotional ability of the patient after the 
stroke has been discussed. (34) . However, the sexual function of these men has recently 
been investigated deeper. Since 1998 Koperlainen et al,  showed that stroke patients and 
their wives have some level of dissatisfaction with sexual function (44). Also, ED in stroke 
patients has been  linked with psychological causes  (45). In this case, it has been speculated 
that impairment of cerebral erectile control functions, physical limitations after the stroke, 
and emotional changes, generate psychogenic and neurogenic ED (34, 46). Studies compared 
unilateral stroke patients compared with those showing stroke lesions in the right cerebral 
hemisphere. The results reported that both patients experienced ejaculation disorders 
besides a significant decrease in sexual desire and intercourse frequency (34, 47).  
Until recently, it was believed that ED was a health problem in patients after stroke. 
However, increasing evidence supports an idea that men with ED have more comorbidities 
than men who do not. More importantly, men with ED were more likely to have strokes 
than those without. In the others words, ED has been cited as a strong indicator of stroke, as 
well as a clinical marker for cerebrovascular diseases (22, 48-49). Ponholzer et al , reported 
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that 2,561 men with moderate to severe ED had an increased risk of stroke over 10 years 
(24.7% and 43.6%) (50). Furthermore, it has been suggested that ED is an independent risk 
factor for stroke. In this study,  1,209 men from the Massachusetts Male Aging Study were 
evaluated over  a 15 year period and it was reported that  those men who have had ED were 
approximately three times more likely to have a stroke  if compared to those without ED (5).  
The penile arteries have a smaller diameter than internal carotid, coronary and others major 
arteries. Thus lumen obstruction may lead to the development of ED prior to cardiac signs or 
stroke (22). Corroborating with this idea Lojanapiwat et al performed studies showing that 
patients who developed ED had endothelial dysfunction prior to the clinical symptoms. Also 
laboratory results for this patients indicated  cardiovascular risks (51). In addition, Vicenzini et 
al suggested that cerebrovascular reactivity was reduced in patients with ED without other 
signs of clinical atherosclerosis (52). Finally Chung et al, suggested that men with ED have a 
significant increased risk for stroke 5 years after ED symptoms first began (22). 
4. Hypertension and ED 
Arterial hypertension is a systemic disorder characterized by altered regulation of 
cardiovascular hemodynamic, including arterial vascular resistance and cardiac index, 
leading to an increase in arterial blood pressure (53). It is accompanied by proliferation, 
migration of VSMCs, and varying levels of inflammation of the arterial wall, processes that 
together constitute vascular remodeling (54). Hypertension is associated with increased 
vasoconstrictor and reduced vasodilator responses (55-57). The pathological changes 
resulting from altered vascular function include injury to the brain, kidney and heart (55). 
Several studies have established a clinical correlation between incidence of hypertension 
and ED (58). According to Buccchardt et al, 30% of hypertensive patients have ED and the 
severity of this sexual disorder is directly proportional to the severity of hypertension. 
Nowadays, this fact has been well accepted because both pathologies are an unbalance 
between endogenous contractile and relaxing substances. In addition, since both are 
pathological vascular disorders, it is supposed that ED in hypertensive patients is highly 
prevalent and more severe than in the other people (3). 
Deficiency of NO has been hypothesized to be a major cause of ED in patients with 
hypertension. Another substance that is important in hypertension and ED is endothelin 
(ET-1). ET-1 is considered a physiological antagonist of NO. ET-1 induces vasoconstriction 
and activates transcriptional factors that coordinate an increase of cytokines and enzymes, 
thus enhancing inflammation, oxidative stress and tissue damage. All these factors are very 
important in hypertension associated vascular dysfunction  (59). Several studies have 
underlined the potential importance of ET-1 in the modulation of corpus cavernosum (CC) 
smooth muscle tone (60), since these cells can synthesize  ET-1. The fetal human and adult 
penile cells, and several animal species, also express endothelin converting enzyme 1, the 
endothelin recepotors A (ETA) and B (ETB) subtypes (61-63). Furthermore, Melegy et al 
showed that ET-1 levels were significantly greater in patients with ED than the normal 
group (64). 
Even though NO is well known as the major vasodilator involved in ED, other mediators 
are also involved. Activation of B1 or B2 kinin receptors by bradykinin (BK) induce NO 
and/or prostacyclin release from endothelial cells (65-66). Teixeira et al reported the 
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existence of functional B2 kinin receptors in human erectile tissues and demonstrated that 
activation of it resulted in NO release. These findings were supported by results from 
Becker et al. They demonstrated that BK is able to promote relaxation in CC. This effect 
appear to involve more cAMP than cGMP (67). However, both cGMP and cAMP are 
associated with relaxation in systemic or penile vessel circulation.  
O-GlcNAcylation is an important regulatory mechanism that also modulates stress 
responses in the cardiovascular system and may have significant influence on vascular 
blood pressure (68). Glucosamine (GlcN) is an amino sugar that can stimulate O-linked-N-
acetylglucosamine (O-GlcNAc) modification of proteins by increasing flux through the 
hexosamine biosynthesis pathway, thus increasing production of UDP-GlcNAc. UDP-
GlcNAc is a substrate for O-GlcNAc transferase (OGT), which catalyzes the O-linked 
addition of GlcNAc to serine and threonine residues of nucleocytoplasmic proteins in higher 
eukaryotes (68). GlcN has anti-inflammatory effects in a variety of inflammatory models and 
cell types. Recently, it has been demonstrated that systemic treatment with glucosamine and 
PUGNAc, which increases O-GlcNAc modification of proteins by inhibiting O-GlcNAcase, 
can inhibit acute inflammatory and neointimal responses to endoluminal arterial injury in 
rat’s carotid artery (69). ET-1-induced changes in vascular contractile responses are 
mediated by O-GlcNAc modification of proteins. Aortas from Doca-salt rats, which exhibit 
ET-1 augment, displayed increased contractions to phenylephrine and enhanced levels of O-
GlcNAC proteins. Treatment of Doca-salt rats with an endothelin A antagonist abrogated 
augmented vascular levels of O-GlcNAc and prevented the increase in phenylephrine 
vasoconstriction, suggesting that ET-1 indeed augments O-GlcNAc levels and this 
modification contributes to the vascular changes induced by this peptide (70). On the other 
hand, O-GlcNAcylation is also involved in ED. A new line of investigation has pointed to 
the significance of hyperglycemia-induced O-GlcNAc associated with modification of eNOS, 
as well as inactivation of the enzyme. It has been demonstrated that O-GlcNAc inactives 
eNOS in diabetes-associated ED (71). However, the exact mechanism through O-
GlcNAcylation is correlated with hypertension or ED is still not well understood. In the last 
decade, another mechanism involved in the regulation of ED has been the renin-angiotensin 
system (RAS). Evidence has shown that there is a RAS inside of the corpus cavenosum. 
According Becker et al human CC is able to produce and secrete physiologically relevant 
amounts of angiotensin II (Ang II) (67). Ang II is the main active metabolite of the renin-
angiotensin cascade. The most important physiologic effect of Angio II is induction of 
vascular smooth muscle contraction. This action contributes to the maintenance of systemic 
blood pressure through various mechanisms in the cardiovascular and renal systems. Ang II 
is also an important modulator of erectile function (72). Reinforcing the association of RAS 
and ED, angiotensin-converting enzyme (ACE) has been found in the endothelial cells of 
dog CC (73), and ACE mRNA expression is up-regulated in a rat model of arteriogenic ED, 
although it is expressed at very low levels in the penis of control rats (74). 
Arginase pathway has been cited as another mechanism that may be involved in both, 
hypertension and ED. Growing evidence suggests that arginage misregulation plays a key 
role in the pathophysiology of essential hypertension and that the involvement of arginase 
in ED has been apparent in recent years. Arginase exists in two isoforms, the hepatic type, 
arginase I and the extrahepatic type, arginase II (75). Both isoforms are expressed in human 
CC tissue (76). Surprisingly, the role of arginase in hypertension is poorly documented. 
Augmented arginase activity (AA)/expression were reported in different vascular beds in 
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models of essential or secondary hypertension (77-78). Recent studies reported that arginase 
inhibitor improved aortic endothelial function via a NO-dependent mechanism in pre-
hypertensive or young adult SHR, and also prevented the development of hypertension (79-80).  
During hypertension or ED, elevated levels of arginase can compete with NOS for available 
L-arginine, reducing NO and increasing superoxide production via NOS uncoupling (81). 
Considering this, arginase pathway can regulate overall NO production. Additionally, 
elevated superoxide combines with NO to form peroxynitrite further reducing NO, and also 
oxidative species increase arginase activity (82). ED mechanisms involve oxidative stress 
and vascular inflammation (83), both of which have been associated with enhanced arginase 
activity and expression in the vasculature (84). Furthermore, up-regulated arginase is 
mechanistically linked to the pathogenesis of vascular dysfunction with hypertension 
through increases in the polyamine and proline precursor L-ornithine, which contributes to 
VSM cell proliferation and intimal thickening (81, 85). There is  evidence of a biological role 
of arginase in regulating erectile function in the aged penile vascular bed, at both the 
molecular and functional level  (83). Also, endothelial arginase II has been proposed as a 
novel target for the treatment of atherosclerosis (80). Taking into account that in 
pathological conditions arginase can influence NO avaibility and consequently disrupt the 
perfect balance necessary to keep the VSM tone, arginase can be considered involved in both 
hypertension and ED. However, a more complete understanding about the exact mechanism 
leading to disruption of vascular dynamics by arginase in ED and hypertension is needed.  
Regarding hypertension and ED, another important factor is the unwanted side effects from 
anti-hypertensive drugs. The treatment for hypertension can be associated with ED because 
some medicines affect erectile function, for example, diuretics. Several studies suggest that 
about 10% to 20% of patients taking thiazide  can  have ED (86), as well as  patients that use 
an aldosterone antagonist (87). Fortunately, the effect of diuretics on ED is completely 
reversible after cessation of administration. ┚-adrenergic receptor blockers have also been 
suggested by several studies to be associated with ED,  specially propranolol (88). However, 
the new generation of ┚-blockers appears to have less effect on erectile function, such as 
nebivolol. This drug  enhances erectile response and reverses ED in diabetic rats, as well as 
potentiates  NO/cGMP-mediated relaxation of human penile  tissues (89). Interestingly, 
angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) 
appear to favorably affect sexual function (90). Patients treated with captopril showed 
improved  sexual function by 40% to 80% compared to non-treated patients (91). The same 
has been observed for hypertensive patients treated with valsartan; reduced ED and 
improved orgasmic function and sexual satisfaction (92). Also, it was found that losartan 
helps preserve erectile function in male rats after bilateral cavernous nerve injury by 
counter-acting fibrotic activator factors (93). However, recent study showed no change in 
ED progression in humans with ACEI or angioten-receptor blocker (ARB)   therapy (94).  
Regarding the -adrenoceptor agents to treat hypertension, has been showed that direct 
cavernosal injection of -antagonists cause erection in both, experimental and humans, 
although this effect is not observed with -selective drugs. Notably, it has been observed 
that patients treated with -blockers of the adrenergic receptors exhibited improvement of 
their sexual activity. On the other hand, especial attention is necessary for hypertensive 
patients treated with vasodilators such as ┙-blockers because if those patients have ED, they 
should not take PDE5 inhibitors, otherwise, combining these drugs will result in 
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hypotension. The treatment with calcium channel blockers, which dilate arteries by 
reducing calcium influx into cells also efectively lower blood pressure. The currently 
available ones inhibit L-type channels in humans and seem to have a neutral effect on 
erection (95). Possibly this is because this channel is linked with nNOS activation from 
cholinergic nerve endings into the penis, which is important for NO release and 
consequently erection. However, although this channel is inhibited, nNOS from nitrergic 
nerves will be activated, allowing the erectile process to begin.  Finally, direct vasodilators 
such as hydralazine and minoxidil have rarely been reported to cause ED. 
5. Heart failure and ED 
Heart failure (HF) is a syndrome manifesting as the inability of the heart to fill with or eject 
blood due to structural or functional cardiac conditions (96). Some authors believe that HF 
can be considered as the last stage of heart disease and a significant cause of mortality and 
morbidity worldwide (97). According to the American Heart Association (AHA), HF is a 
condition that affects nearly 5.7 million Americans of all ages (98). Nevertheless, in the last 
decade improvement in survival of myocardial infarction and HF has been observed, 
concurrent with consequences from these diseases. It is believed that the prevalence of these 
diseases will continue to increase in the population, with an estimated number of more than 
10 million patients by the year 2037. Coronary artery disease, with or without myocardial 
infarctions, with a subsequent development of ischemic cardiomyopathy or loss of 
contractile proteins, remains the major cause of chronic HF progression, especially among 
the elderly population (99). Looking at chronic heart failure (CHF) the numbers are equally 
alarming. The AHA has estimated more than 4.9 million people in the US have CHF (98). As 
this pathophysiology progresses, patients experience an increase in fatigue, shortness of 
breath, palpitations, or angina, decreasing their quality of life and potentially interfering 
with their sexual  performance (90).  
While HF per se can have many effects on a patient’s lifestyle, ED can further aggravate 
these effects and contribute to poor quality of life and depression. Studies showed the 
prevalence of ED is around  67% in men 65  or  older,  and 68% in men older than 79 (100). 
The prevalence of ED in patients with HF appears to be significantly higher. Baraghoush et 
al, found a prevalence of 84% general sexual dysfunction in the male population with an 
average of 59 years of age and chronic compensated HF (99, 101).  
It is common sense that the physiology behind an erection is a primarily vascular 
phenomenon. In patients with HF, several factors that come into play at the microvascular 
level, such as reduced arterial compliance, endothelial dysfunction, and generalized focal 
atherosclerosis (99). There are few theories that explain the mechanism of endothelial 
dysfunction in patients with HF. Impaired relaxation mediated by L-arginine-NO was found 
in smooth muscle cells (SMC) and in the penis from animals and humans with atherosclerotic 
coronary arteries (102). However, systemic endothelium-dependent vasodilatation has been 
shown to decrease ED in men with and without clinical CVD (103). In addition, decreased NO 
production via  downregulation of endothelial NO synthase (eNOS) and cyclooxygenase 
(COX) was observed after the onset of pacing-induced HF in dogs (104). Rho-kinase signaling 
is very important in erectile function because in the absence of arousal, the penis remains in 
the non-erect state by cavernosal vasoconstriction induced mainly by norepinephrine and 
endothelin 1 (ET-1), which are Rho-kinase mediated responses. Thus, its upregulation leads to 
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ED (105). Also, this pathway is involved in the regulation of myofibrillar Ca+2 sensitivity in 
cardiac muscle and contributes to irreversible myocardial damage. Rho-kinase is involved also 
in the pathogenesis of cardiovascular remodeling and its inhibition plays a significant role in 
treatment of the failing heart by limiting infarct size, which is the major contributor to the 
development of heart failure. The cardioprotective effect of Rho-kinase inhibition involves 
PI3K/AKT and NOS activation. However, Rho-kinase inhibitor compounds need to be 
evaluated for their efficacy during varying index ischemia periods, a wide dose range, and in 
vivo animal models mimicking the clinical setting more closely (105).   
Becker et al reported that patients with HF have vasomodulators, systemic levels unbalanced  
and this change can  lead to increased SMC tone and vasoconstriction in the penile vessels 
through a variety of mechanisms (106). According to Pedersen et al, the ET-1, RhoA/Rho-
kinase and ROS are not the only mechanism that can be modified, vasopressin also is elevated 
in patients with HF (107). Compared to patients with CHF, the situation is very similar. In 2005 
Rastogi et al suggested that multiple factors may be involved in the onset of ED in patients 
with CHF. These patients have arterial compliance abnormalities and often atherosclerosis, 
which reduce blood flow into the CC (108). In addition, endothelial dysfunction decreased the 
production or increases the breakdown of NO. Other vasoconstrictors are also increased in 
patients with CHF and can be interfering with their ability to achieve and maintain an erection 
(109). Finally, several medicines commonly used to treat HF have been shown to either cause 
or worsen ED (99). Digoxin for example, is a drug that can cause ED even though the 
mechanism by which this happen is not really clear, but it has been speculated that this drug 
creates a sexual hormonal unbalance (110) and the inhibition of cavernosal sodium/ 
potassium-adenosine triphosphate activity, consequently impairing NO relaxation (111).  
 
Table 1. Relationship between the first report of ED and subsequent cardiovascular 
disease. Incident ED was statistically significant associated with subsequent angina, 
myocardial infarction and stroke (red circles). Also, number of patients who showed ED 
prior the cardiovascular event was extremely higher compared to those who shoed ED after 
cardiovascular event (red circle). Men with incident ED had a significantly increased risk of 
myocardial infarctation or angina relative to men without a report of ED. Adapted from 
Thompson et al, 2005 (112).   
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6. The link between ED and CVD 
An emerging basic science and clinical database provides a strong argument for endothelial 
and smooth muscle dysfunction as a central etiologic factor in systemic and peripheral 
diseases, including ED (113). The endothelium is the single layer of cells that line the 
luminal surface of blood vessels. It is far more than just a structural lining; it has a range of 
important physiological functions. It acts as a direct interface between the components of 
circulating blood and local tissue, and regulates numerous local blood vessel functions, 
including vascular tone, cell adhesiveness, coagulation, inflammation and permeability. The 
endothelium produces and responds to several potent, locally and active mediators. The 
most important of these is NO, which is a nonadrenergic-noncholinergic (NANC) 
vasodilator neurotransmitter involved in the regulation of vascular wall function (113). This 
highly reactive gas  presents potent anti-atherogenic properties, in addition to inhibiting 
platelet aggregation and regulating vascular tone (114). Moreover, in the atherosclerosis 
installation process there are leucocytes adhesion and inflammatory agents that contribute 
to plaque instability and rupture, and this event can be inhibited by NO.  
The vasodilatation induced by NO is initiated with the synthesis from L-arginine by nitric 
oxide synthases (NOS) (115). Physiological amounts of NO can be produced by endothelium 
(eNOS) or neuronal (nNOS) enzymes and both are involved in penile erection. Down 
regulation of eNOS in pathological conditions results in reduced bioavailability of NO and 
consequently endothelial dysfunction (8). Inhibition of nNOs attenuated erectile responses 
(116). Erectile function was also found to be preserved in mice lacking eNOS. However, 
incracavernosal pressure during erection was significantly decrease in eNOS-deficient mice 
and over all, NOS activity was only 60% of the activity observed in wild type mice. Thus, 
physiologic penile erection is mediated by both nNOS and eNOS (7, 117).  
NO activates a soluble guanylyl cyclase that forms cyclic guanosine monophosphate 
(cGMP) (118) in vascular smooth muscle cells, resulting in penile relaxation (8, 23). Reports 
of ED in cGMP-dependent kinase-I (cGKI)-deficient mice suggest that cGMP is indeed the 
main second messenger in ED (119). These findings are supported by clinical data showing 
that phosphodiesterase type 5 inhibitor (PDE5, e.g. sildenafil) prevents the degradation of 
cGMP (120). In cGKI-deficient mice cAMP-mediated pathway cannot compensate deficient 
cGMP-dependent signaling in vivo (119). However, in humans prostaglandin E1 and its 
derivative alprostadil, which induce relaxation predominantly via cAMP pathway, were 
found to be highly effective in the treatment of ED (121-122).  
Dysfunction of the endothelium may be interpreted as homeostasis disturbance due to 
breakdown. Also, endothelial dysfunction  can be caused by vascular insults, such as 
diabetes, smoking, hyperlipidemia and hypertension (123). At the cellular level, endothelial 
dysfunction outcomes in impaired release of NO, which may be considered a key 
pathomechanism in both endothelial (124-125) and erectile dysfunction (115, 126). Oxidative 
stress, which is directly toxic to the endothelium and also interferes with the NO pathway, is 
a causal factor in clinically evident occlusive CVD and vascular damage associated with 
preclinical disease. Free radical damage, impaired function and availability of NO can also 
result in increased adhesion, aggregation of platelets and neutrophils, besides the release of 
vasoconstrictor substances (29-30, 113). In addition NOS depends on tetrahydrobiopterin as 
a co-factor. Endothelial dysfunction associated with tetrahydrobiopterin depletion could be 
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reversed by supplementation of this substance (127-129). Indeed the treatment with 
tetrahydrobiopterin increased NOS activity by 30% in rabbit CC (130). 
Over the past years studies have showed that many men will realize the onset of ED occurs 
before they are diagnosed with CVD. The anatomic structure of the penis and the 
physiology of getting and maintaining an erection provide clues as to the reason the penile 
vascular bed has some unique properties that facilitate early detection of systemic vascular 
disease (113). Nowadays, it is well known that ED can result from any number of structural 
or functional abnormalities in the penile vascular bed. For instance, ED may be a 
consequence of the cavernosal arteries oclusion by atherosclerosis, impairment of 
endothelial-dependent and/or independent smooth muscle relaxation, or a combination of 
these two factors. It is believed that ED caused by functional vascular factors occurs early 
and is likely associated with oxidative stress and decreased NO availability. Initially these 
factors result in poor relaxation of penile endothelium and in smooth muscle that presents 
clinically as ED, with difficulty to maintain a firm erection. This early clinical symptom 
probably occurs before the development of structural, occlusive penile arterial disease and 
may be among the earliest signs of systemic CVD. Thus, it has been accepted that 
endothelial dysfunction is the etiologic connection between ED and systemic cardiovascular 
diseases (9, 30).  
Corroborating this idea, Lojanapiwat et al examined 41 ED patients and 30 age-matched 
normal control, subjects were investigated for cardiovascular risks and endothelial function. 
Changes in brachial arterial diameter after its occlusion were compared between the groups. 
Results did not show differences in baseline characteristics for cardiovascular risks and lipid 
levels. However, a significant difference regarding endothelial dysfunction in ED patients 
without clinical cardiovascular risks versus control patients was observed. They concluded 
that patients who developed ED showed endothelial dysfunction and cardiovascular risk 
markers prior to the clinical symptoms. In addition, a study evaluating systemic vascular 
structure and function in 30 patients with ED and 27 age-matched normal controls, 
investigated whether patients with vascular ED and no other clinical CVD have structural 
and functional abnormalities of other vascular beds. Systemic endothelial function using 
flow mediated brachial artery vasodilatation showed that men with ED exhibited 
significantly lower brachial artery flow-mediated, vascular defect in endothelium-
dependent and independent vasodilatation, which happen before the development of 
structural or functional systemic vascular disease, when compared to controls. According to 
the authors these data suggest the presence of  peripheral vascular abnormality in the NO 
pathway (131). In another study, biochemical markers of endothelial cell activation were 
used to compare 45 men with ED and no clinical CVD with 25 age-matched healthy. The 
results showed that the carotid intima-media thickness (IMT) was similar between the 
groups. However, soluble P-selectin (intracellular adhesion molecule-1) and endothelin-1 
levels were significantly higher in  men with ED and no CVD (132).  
Alterations in the several signalling pathways, mainly in Rho-kinase signaling, are common 
in ED as well as CDV, contributing to a further increase in endothelial dysfunction. Rho-
kinase, is involved in the sequence of events that stimulates vascular smooth muscle 
contraction, stress fiber formation, cell migration, and, indirectly, blood pressure regulation. 
In this way, RhoA/Rho-kinase activation has significant effects on various cardiovascular 
diseases, such as arterial hypertension (133), atherosclerosis (134), heart attack (135), stroke 
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(136), coronary vasospasm (137), myocardial hypertrophy (138), myocardial ischemia-
reperfusion injury (139), vascular remodeling (140) and ED. Since the main function of Rho-
kinase is the regulation of smooth muscle tone (141), the upregulation of the Rho-kinase 
pathway increases cavernosal smooth muscle contraction, leading to ED (142-143). 
Furthermore, studies indicate that Rho-kinase isoforms are activated in patients with a 
cardiovascular disorder or associated risk factors (144-145). Also, RhoA mRNA expression 
and activity is increased in aortas from aged rats, suggesting a role of RhoA in the 
development of age-related cardiovascular disease (146).  
7. Conclusion 
Although the link between ED and CVD has been previously documented, convincing 
evidence of the direction and magnitude of the effect has not been available. However, 
several studies support the idea that ED precedes overt structural occlusion of larger blood 
vessels, and ED is often an early manifestation of systemic vascular disease. The evaluation 
of ED in the medical history as an early symptom of endothelial dysfunction and 
atherosclerosis may be a predictor of future cardiovascular events, including death. This 
might be relevant to identifying patients with a particularly high risk of experiencing 
cardiovascular events even though is not clear yet what kind evaluation or parameters 
should be prompted in ED condition. 
 
Fig. 1. Endothelial dysfunction is a common situation in both CVD and ED. Generally ED 
is caused by unbalance between vasoconstrictors (Ang II, ET-1, Rho-kinase, arginase) and 
vasodilators (NO) endogenous agents. Endothelial dysfunction leads to ED development 
and later to onset of CVD.  
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